Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07027163 · ClinicalTrials.gov registry record
A Study About the Use of Omalizumab in the Treatment of Food Allergy and Anaphylaxis
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 62
- Enrollment target
NCT07027163 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 62 participants.
The verdict
NCT07027163 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 62 participants
- Enrollment target
Study Summary
This was a retrospective, multi-center observational study conducted across four allergy departments in Europe (Berlin, Leipzig, Barcelona, and Basel). The study included patients with immunoglobulin E (IgE)-mediated food allergy who were treated with omalizumab, either as monotherapy or in combination with oral immunotherapy (OIT) between 2002-2022.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2023-06-01 |
| Est. Completion | 2023-09-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07027163
The ClinicalTrials.gov registry entry for NCT07027163 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT07027163 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07027163 about?
NCT07027163 is a clinical study titled "A Study About the Use of Omalizumab in the Treatment of Food Allergy and Anaphylaxis". This was a retrospective, multi-center observational study conducted across four allergy departments in Europe (Berlin, Leipzig, Barcelona, and Basel). The study included patients with immunoglobulin E (IgE)-mediated food allergy who were treated with omalizumab, either as monotherapy or in combinat...
What is the current status of trial NCT07027163?
This trial is currently completed. The enrollment target is 62 participants. The study started on 2023-06-01. Estimated completion is 2023-09-01.
Who is sponsoring clinical trial NCT07027163?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.